These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27180307)

  • 21. Drug repurposing in cancer.
    Sleire L; Førde HE; Netland IA; Leiss L; Skeie BS; Enger PØ
    Pharmacol Res; 2017 Oct; 124():74-91. PubMed ID: 28712971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug Repurposing in Anticancer Reagent Development.
    Chen PC; Liu X; Lin Y
    Comb Chem High Throughput Screen; 2017; 20(5):395-402. PubMed ID: 28025934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy in combating cancer.
    Bayat Mokhtari R; Homayouni TS; Baluch N; Morgatskaya E; Kumar S; Das B; Yeger H
    Oncotarget; 2017 Jun; 8(23):38022-38043. PubMed ID: 28410237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
    Roix JJ; Harrison SD; Rainbolt EA; Meshaw KR; McMurry AS; Cheung P; Saha S
    PLoS One; 2014; 9(8):e101708. PubMed ID: 25093583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
    Likus W; Siemianowicz K; Bieńk K; Pakuła M; Pathak H; Dutta C; Wang Q; Shojaei S; Assaraf YG; Ghavami S; Cieślar-Pobuda A; Łos MJ
    Drug Resist Updat; 2016 Mar; 25():13-25. PubMed ID: 27155373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing of FDA-approved drugs against cancer - focus on metastasis.
    Ozsvári B; Lamb R; Lisanti MP
    Aging (Albany NY); 2016 Apr; 8(4):567-8. PubMed ID: 27038638
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug Repositioning for Ovarian Cancer Treatment: An Update.
    Cavalluzzi MM; Viale M; Rotondo NP; Ferraro V; Lentini G
    Anticancer Agents Med Chem; 2024; 24(8):637-647. PubMed ID: 38367265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systems-level analysis of drug-target-disease associations for drug repositioning.
    Rutherford KD; Mazandu GK; Mulder NJ
    Brief Funct Genomics; 2018 Jan; 17(1):34-41. PubMed ID: 28968683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
    Wong MS; Sidik SM; Mahmud R; Stanslas J
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges.
    Gandalovičová A; Rosel D; Fernandes M; Veselý P; Heneberg P; Čermák V; Petruželka L; Kumar S; Sanz-Moreno V; Brábek J
    Trends Cancer; 2017 Jun; 3(6):391-406. PubMed ID: 28670628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of drug candidates and repurposing opportunities through compound-target interaction networks.
    Cichonska A; Rousu J; Aittokallio T
    Expert Opin Drug Discov; 2015 Dec; 10(12):1333-45. PubMed ID: 26429153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticancer Drug Discovery By Structure-Based Repositioning Approach.
    Modh DH; Kulkarni VM
    Mini Rev Med Chem; 2024; 24(1):60-91. PubMed ID: 37165589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repurposing of plant alkaloids for cancer therapy: Pharmacology and toxicology.
    Efferth T; Oesch F
    Semin Cancer Biol; 2021 Jan; 68():143-163. PubMed ID: 31883912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposing psychiatric drugs as anti-cancer agents.
    Huang J; Zhao D; Liu Z; Liu F
    Cancer Lett; 2018 Apr; 419():257-265. PubMed ID: 29414306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals.
    Duenas-Gonzalez A; Gonzalez-Fierro A; Bornstein-Quevedo L; Gutierrez-Delgado F; Kast RE; Chavez-Blanco A; Dominguez-Gomez G; Candelaria M; Romo-Pérez A; Correa-Basurto J; Lizano M; Perez-de la Cruz V; Robles-Bañuelos B; Nuñez-Corona D; Martinez-Perez E; Verastegui E
    Expert Rev Anticancer Ther; 2024 Aug; 24(8):665-677. PubMed ID: 38913911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-mitotic agents: Are they emerging molecules for cancer treatment?
    Penna LS; Henriques JAP; Bonatto D
    Pharmacol Ther; 2017 May; 173():67-82. PubMed ID: 28174095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities.
    Barbosa EJ; Löbenberg R; de Araujo GLB; Bou-Chacra NA
    Eur J Pharm Biopharm; 2019 Aug; 141():58-69. PubMed ID: 31078739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Repurposing in the Development of Anticancer Agents.
    Olgen S; Kotra LP
    Curr Med Chem; 2019; 26(28):5410-5427. PubMed ID: 30009698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer.
    Chen HR; Sherr DH; Hu Z; DeLisi C
    BMC Med Genomics; 2016 Jul; 9(1):51. PubMed ID: 27475327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Old wine in new bottles: Drug repurposing in oncology.
    Antoszczak M; Markowska A; Markowska J; Huczyński A
    Eur J Pharmacol; 2020 Jan; 866():172784. PubMed ID: 31730760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.